All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?

Dec 23, 2021
Share:

During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to steering committee member Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?

What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?

In this podcast, Mohty highlights the latest advances in the field of steroid-refractory acute GvHD and emphasizes the importance of prevention, commenting on anti-thymocyte globulin (ATG), allogeneic hematopoietic stem cell transplant (allo-HSCT), and posttransplant cyclophosphamide. Mohty also mentions the HERACLES trial (NCT03225937) and the use of the JAK inhibitor ruxolitinib.